Skip to Content

BioNTech SE ADR BNTX Stock Quote

| Rating as of

NASDAQ: BNTX

Morningstar‘s Stock Analysis BNTX

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Raising Our BioNTech FVE to $217 After Adjusting for Expected U.S. COVID-19 Vaccine Pricing in 2023

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

We’ve raised our fair value estimate for BioNTech to $217 from $205 following solid third-quarter results, as we have raised our assumed U.S. prices for booster doses of BioNTech and partner Pfizer’s COVID-19 vaccines beginning in 2023. Management raised its 2022 revenue guidance to EUR 16-17 billion, the high end of its prior range, due to uptake of the bivalent booster and higher prices. The updated guidance is in line with our prior forecast of EUR 16.2 billion in revenue for the full year, as Pfizer/BioNTech have been able to better support the initial bivalent vaccine launch than Moderna (which has had temporary supply constraints).

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BNTX

Company Profile BNTX

Business Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact
An der Goldgrube 12
Mainz, RP, D-55131, DEU
Industry Biotechnology
Employees 4,000

Related Articles BNTX

FAQs for BioNTech SE ADR Stock

No. BNTX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BNTX’s market cap is 39.47 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

BNTX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BNTX’s historical performance against its industry peers and the overall market.